SCHEMBL966599

SCHEMBL966599

CCOC(=O)/C=C/c1c(C)nn(C)c1-n1ccc2ccc(OC(C)COC)cc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.37
CCNC P24863 4/20 0.35
CDK8 P49336 4/20 0.35
GCK P35557 9/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HSD17B1 P14061 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B2 P37059 1/20 0.34
PDE4B Q07343 1/20 0.34
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PHGDH O43175 1/20 0.33
PIM3 Q86V86 1/20 0.32
CDK19 Q9BWU1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964594 0.91 CCNC (0.35) ABL1CCNCCDK8GCKCYP1A2
SCHEMBL962698 0.91 ABL1 (0.38) ABL1GCKSMN1; SMN2PIM3
SCHEMBL962695 0.91 ABL1 (0.38) ABL1GCKSMN1; SMN2PIM3
SCHEMBL962379 0.90 PIM3 (0.39) CCNCCDK8CYP1A2CYP3A4CYP2D6
SCHEMBL963541 0.89 CYP1A2 (0.43) CCNCCDK8CYP1A2CYP3A4CYP2D6
SCHEMBL966848 0.88 TDP1 (0.36) CCNCCDK8CYP1A2CYP3A4CYP2D6
SCHEMBL966849 0.88 TDP1 (0.36) CCNCCDK8CYP1A2CYP3A4CYP2D6
SCHEMBL963486 0.88 MCL1 (0.37) CCNCCDK8CYP1A2CYP3A4CYP2D6
SCHEMBL966841 0.87 CCNC (0.38) ABL1CCNCCDK8CYP1A2CYP3A4
SCHEMBL965488 0.85 POLB (0.34) CCNCCDK8CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG ABL1 4132/4885CCNC 3591/4885CDK8 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.